Supply constraints started to ease for $NVO (-18,32 %), and it gradually increased the supply of Wegovy in the first half of the year. This has been reflected in weekly prescription numbers, which have increased considerably year-to-date.

I see room for outperformance in the second half of the year, but far more in 2025 and 2026.